Prelude Therapeutics Inc (PRLD) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	8-K	10-K	8-K	10-K	10-K	S-1
Revenues [+]	0.0	92.9	0.0	86.8	0.0	0.0	0.0
Royalties		92.9		86.8
Revenue growth		7.0%
Cost of goods sold	0.0	123.5	0.0	113.7	0.0	0.0	0.0
Gross profit	0.0	-30.7	0.0	-27.0	0.0	0.0	0.0
Gross margin		-33.0%		-31.1%
Selling, general and administrative [+]	123.5	30.7	113.7	27.0	10.6	3.8	2.4
General and administrative		30.7		27.0	10.6	3.8	2.4
Research and development					48.2	24.3	12.6
Other operating expenses	-123.5	62.2	-113.7	59.8
EBITDA [+]	1.3		0.9		-58.2	-27.7	-14.8
EBITDA growth	44.7%	8.6%	-101.6%		110.0%	87.0%
EBITDA margin		-133.0%		-131.1%
Depreciation and amortization	1.3		0.9		0.5	0.4	0.1
EBIT [+]	0.0	-123.5	0.0	-113.7	-58.8	-28.1	-15.0
EBIT growth		8.6%	-100.0%		109.1%	87.7%
EBIT margin		-133.0%		-131.1%
Other income (expense), net	-115.4	8.1	-111.7	2.0	1.8	0.5	0.3
Pre-tax income	-115.4	-115.4	-111.7	-111.7	-56.9	-27.6	-14.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-115.4	-115.4	-111.7	-111.7	-56.9	-27.6	-14.7
Net margin		-124.3%		-128.7%

Basic EPS [+]	($2.44)	($2.44)	($2.43)	($2.43)	($4.56)	($16.52)	($10.46)
Growth	0.5%	0.5%	-46.8%		-72.4%	57.9%
Diluted EPS [+]	($2.44)	($2.44)	($2.43)	($2.43)	($4.56)	($16.52)	($10.46)
Growth	0.5%	0.5%	-46.8%		-72.4%	57.9%

Shares outstanding (basic) [+]	47.4	47.4	46.0	46.0	12.5	1.7	1.4
Growth	2.9%	2.9%	269.0%		647.9%	18.9%
Shares outstanding (diluted) [+]	47.4	47.4	46.0	46.0	12.5	1.7	1.4
Growth	2.9%	2.9%	269.0%		647.9%	18.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.